Physician profile
Gary Gotthelf
NPI 1932102746
$4,308.89
in general payments reported to CMS, 2019-2025
46 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,308 · 2020: $825 · 2021: $1,163 · 2022: $662 · 2023: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $350.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $433.86 | 2019-2023 | |
| Novo Nordisk INC | $366.24 | 2019-2023 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $364.30 | 2019-2022 | |
| Glaxosmithkline, LLC. | $280.23 | 2019-2023 | Trelegy Ellipta |
| Radius Health, INC. | $268.60 | 2019-2023 | Tymlos |
| Lilly USA, LLC | $252.19 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $207.07 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $206.31 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $145.54 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.45 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $134.41 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $129.78 | 2019-2022 | |
| Abbott Laboratories | $93.15 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $81.06 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.88 | 2019-2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Gotthelf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.